Information Provided By: 
Fly News Breaks for January 17, 2018
APHB
Jan 17, 2018 | 07:09 EDT
H.C. Wainwright analyst Joseph Pantginis raised his price target for AmpliPhi Biosciences to $6 saying 2018 "may represent a tipping point for the shares." The analyst expects this year to bring a "significant boost in visibility on the story." Building the clinical database with more results and meeting with the FDA to define the potential registration path forward for bacteriophage are the two key drivers, Pantginis tells investors in a research note. He keeps a Buy rating on AmpliPhi.
News For APHB From the Last 2 Days
There are no results for your query APHB
